Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528333 · ClinicalTrials.gov registry record · Phase 2
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
A Phase 2 study of Acute Myeloid Leukemia, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
- 20
- Study locations
NCT00528333 is a Phase 2 study of Acute Myeloid Leukemia that has completed, run by Seagen. The registered enrollment target is 211 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT00528333, a Phase 2 study of Acute Myeloid Leukemia, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lintuzumab (SGN-33)
- DRUG Low dose cytarabine
Study Locations (20)
California
- Tower Cancer Research Foundation - Beverly Hills
- Glendale Memorial Hospital - Glendale
- Kenmar Research Institute - Los Angeles
- University of California Los Angeles - Los Angeles
- Bay Area Cancer Research Group - Pleasant Hill
Florida
- Lakeland Regional Cancer Center - Lakeland
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Illinois
- Rush University Medical Center - Chicago
- Joliet Oncology-Hematology Associates - Joliet
New York
- Northshore University Hospital, Monter Cancer Center - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
Alabama
- Southern Cancer Center - Mobile
Colorado
- University of Colorado Cancer Center - Aurora
Michigan
- Michigan State University, Breslin Cancer Center - Lansing
Montana
- Billings Clinic Cancer Research - Billings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528333
The ClinicalTrials.gov registry entry for NCT00528333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (83% higher). The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00528333 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00528333 about?
NCT00528333 is a clinical study titled "A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML". The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
What is the current status of trial NCT00528333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2007-09. Estimated completion is 2010-08.
What conditions does trial NCT00528333 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT00528333?
The interventions under investigation include: Placebo (DRUG), Lintuzumab (SGN-33) (DRUG), Low dose cytarabine (DRUG).
Who is sponsoring clinical trial NCT00528333?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00528333 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.